[1] FDA. Drugs@FDA: FDA-Approved Drugs[EB/OL]. (2002-03-12)[2020-01-03]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf. [2] National Medical Products Administration. Notification of Adverse Drug Reactions (No.11) [EB/OL]. (2006-11-17)[2020-01-03]. http://www.nmpa.gov.cn/WS04/CL2155/318826.html. [3] WU Y, WU T, ZHAN SY, et al.Analysis of the safety and benefit-risk of ribavirin[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2006, 15(4):210-213. [4] LIU LR, WU T, ZHAN SY, et al.Safety and efficacy of ribavirin: a systemic review of meta-analysis results[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2006, 8(3): 184-187. [5] LI YL, DU JH, QIE GH.Research progress of ribavirin, a broad-spectrum antiviral nucleoside drug[J]. Tibetan Medicine(西藏医药杂志), 2012, 33(2): 37-38. [6] LI YP.Analysis of 160 cases of upper respiratory tract infection treated with ribavirin[J]. China Practical Medicine(中国实用医药), 2011, 6(11): 186. [7] LI QF, LIU H, ZHANG DD, et al.Analysis and suggestions on risk of ribarivin in children[J]. Chinese Journal of Pharmacovigilance, 2018, 15(2): 83-89. [8] AN SH, AI T, BAO YX, et al.The expert consensus on the standard diagnosis and treatment of common cold in Chinese children(2013 version)[J]. Chinese Journal of Practical Pediatrics Sep(中国实用儿科杂志), 2013, 28(9): 680-686. [9] National Health Commission of the People’s Republic of China. Guidelines for the prevention and treatment of hand-foot-and-mouth disease (2018 version)[J]. Infectious Disease Information(传染病信息), 2018, 31(3): 193-198. [10] Respiratory Physician Branch of Chinese Medical Doctor Association. The expert consensus on rational use of anti-influenza virus drugs in the treatment of influenza(2016 version)[J]. Chinese Journal of Internal Medicine(中华儿科杂志), 2016, 55(3): 244-248. [11] The Subspecialty Group of Infectious Diseases, the Society of Pediatrics, Chinese Medical Association: National Center for Quality Control of Infectious Diseases. Expert consensus on diagnosis and treatment of herpetic pharyngitis (2019 version)[J]. Chinese Journal of Pediatrics(中华儿科杂志), 2019, 57(3): 177-180. [12] National Health Commission, National Administration of Traditional Chinese Medicine. The guidelines for the diagnosis and treatment of adenovirus pneumonia in children(2019 version)[J]. Infectious Disease Information(传染病信息), 2019, 32(4): 293-298. [13] Public Health England. PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza[EB/OL]. (2019-01-01)[2020-01-05]. http://guide.medlive.cn/. [14] KDIGO. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Offical Journal of The International Society of Nephrology, 2008, 73(109): 1-99. [15] Ministry of Health of the People’s Republic of China. Practice Guidelines: Prevention and control of Marburg hemorrhagic fever[EB/OL]. (2008-01-01)[2020-01-05]. www.nhc.gov.cn/xxgk/pages/viewdocument.jsp?dispatchDate=&staticUrl=/zwgkzt/wsbysj/200804/27388.shtml&wenhao. [16] American Association for the Study of Liver Diseases. Treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guidelines[J]. Hepatology, 2011, 54(4):1433-1444. [17] Asian Pacifific Association for the Study of the Liver. APASL consensus statements and management algorithms for hepatitis C virus infection[J]. Hepatol Int, 2012, 63(1): 199-236. [18] European Association for the Study of the Liver. Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement[J]. Journal of Hepatology, 2012, 57(6): 1379-1390. [19] NASPGHAN. NASPGHAN Practice guidelines: diagnosis and management of hepatitis c infection in infants, children, and adolescents[J]. Journal of Pediatr Gastroenterol Nutr, 2012, 54(6): 838-855. [20] AASLD-IDSA.Hepatitis C guidance: AASLD-IDSA recomm-endations for testing, managing, and treating adults infected with hepatitis C virus[J]. Hepatology, 2015, 63(2): 1-78. [21] GESA-ASID.Australian recommendations for the management of hepatitis C virus infection: a consensus statement[J]. Med J Aust, 2016, 204(7): 268-272. [22] European Association for the Study of the Liver. EASL recomme-ndations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2): 461-511. [24] The committee of expert consensus for the diagnosis and treatment of chronic kidney disease with hepatitis C infection. The expert consensus for the diagnosis and treatment of chronic kidney disease with hepatitis C infection[J]. Journal of Clinical Nephrology(临床肾脏病杂志), 2019, 19(5): 305-310. [25] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2019, 35(12): 2670-2686. [26] Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver[J]. CMAJ, 2018, 90(22): 677-687. [27] WHO. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease[J/OL]. (2011-01-01)[2020-01-05].https://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=52&codcch=150-29k. [28] GUO JR, ZHANG JW, ZHAO L.Analysis of 1071 reports of ADR/ADE induced by ribarivin[J]. Chinese Journal of Pharmaco-epidemiology(药物流行病学杂志), 2019, 28(4): 245-249. [29] FENG YL, XU XL.ADR case reports occurred in our hospital: analysis of 3437 cases[J]. China Pharmacy(中国药房), 2010, 21(34): 3238-3241. |